C12N 2800/22
Vectors comprising a coding region that has been codon optimised for expression
Official title: Vectors comprising a coding region that has been codon optimised for expression in a respective host
C12N2800/22 (Vectors comprising a coding region that has been codon optimised for expression) appears on 450 US grants and 995 published applications in this corpus.
Search patents in C12N- Granted patents
- 450
- Published applications
- 995
- Assignees
- 483
- Inventors
- 1,827
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 2 |
| 2004 | 0 | 2 |
| 2005 | 1 | 2 |
| 2006 | 1 | 3 |
| 2007 | 3 | 2 |
| 2008 | 1 | 4 |
| 2009 | 3 | 3 |
| 2010 | 0 | 6 |
| 2011 | 3 | 13 |
| 2012 | 4 | 10 |
| 2013 | 3 | 15 |
| 2014 | 13 | 35 |
| 2015 | 14 | 29 |
| 2016 | 16 | 40 |
| 2017 | 25 | 54 |
| 2018 | 29 | 61 |
| 2019 | 36 | 70 |
| 2020 | 38 | 68 |
| 2021 | 37 | 82 |
| 2022 | 50 | 95 |
| 2023 | 39 | 83 |
| 2024 | 42 | 106 |
| 2025 | 60 | 115 |
| 2026 | 31 | 95 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Recombinant vector comprising codon-optimized TIF1γ polynucleotide, and use thereof29 Sep 2026US 12,747,274 B2Kim, Cell & Gene Co., Ltd.
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Method for inducing targeted meiotic recombinations1 Sep 2026US 12,723,267 B2Centre National De La Recherche Scientifique
- Lentiviral vectors in hematopoietic stem cells to treat Wiskott-Aldrich syndrome (WAS)25 Aug 2026US 12,714,732 B2The Regents of the University of California
- Compositions and methods for the treatment of cystic fibrosis11 Aug 2026US 12,703,726 B2University of Iowa Research Foundation
- Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy8 Oct 2026US 2026/0308212 A1Research Institute At Nationwide Children's Hospital
- Orally-delivered vaccines for domesticated and wild animals to prevent pathogen spread using recombinant probiotic bacteria1 Oct 2026US 2026/0295027 A1
- Mutated fragment of vzv glycoprotein e1 Oct 2026US 2026/0295035 A1
- Gene therapy for treating mucopolysaccharidosis type ii1 Oct 2026US 2026/0295085 A1The Trustees of the University of Pennsylvania
- Aav-epo for treating companion animals1 Oct 2026US 2026/0297149 A1The Trustees of the University of Pennsylvania
Most cited
By later US patents
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation451US 8,889,418 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation422US 8,895,308 B1Massachusetts Institute of Technology · 2014
- Nucleic acid-guided nucleases247US 9,982,279 B1Inscripta, Inc. · 2018
- Engineered CRISPR-Cas9 nucleases157US 9,512,446 B1The General Hospital Corporation · 2016